{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Solution+Vehicle&page=5",
    "query": {
      "intervention": "Solution Vehicle",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 455,
    "total_pages": 46,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Solution+Vehicle&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Solution+Vehicle&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T05:22:27.032Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01685242",
      "title": "A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Allergic Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "AC-170 0.24%",
          "type": "DRUG"
        },
        {
          "name": "AC-170 0%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aciex Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2012-09",
      "completion_date": "2012-11",
      "has_results": true,
      "last_update_posted_date": "2017-10-10",
      "last_synced_at": "2026-10-23T05:22:27.032Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01685242"
    },
    {
      "nct_id": "NCT03916042",
      "title": "A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye"
      ],
      "interventions": [
        {
          "name": "Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Ophthalmic Solution (0.25% Novel Formulation) QID to BID",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aldeyra Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 206,
      "start_date": "2019-04-23",
      "completion_date": "2019-11-22",
      "has_results": true,
      "last_update_posted_date": "2025-03-03",
      "last_synced_at": "2026-10-23T05:22:27.032Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03916042"
    },
    {
      "nct_id": "NCT02309385",
      "title": "Safety and Efficacy Study of DSP-Visulex for the Treatment of Anterior Uveitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-Infectious Anterior Uveitis"
      ],
      "interventions": [
        {
          "name": "8% Dexamethasone Sodium Phosphate - Visulex",
          "type": "DRUG"
        },
        {
          "name": "15% Dexamethasone Sodium Phosphate - Visulex",
          "type": "DRUG"
        },
        {
          "name": "Prednisolone Acetate (1%) Eye Drops",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aciont Inc",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2014-10",
      "completion_date": "2017-03-03",
      "has_results": false,
      "last_update_posted_date": "2017-04-27",
      "last_synced_at": "2026-10-23T05:22:27.032Z",
      "location_count": 6,
      "location_summary": "Cambridge, Massachusetts • Charlotte, North Carolina • Fargo, North Dakota + 3 more",
      "locations": [
        {
          "city": "Cambridge",
          "state": "Massachusetts"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Fargo",
          "state": "North Dakota"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02309385"
    },
    {
      "nct_id": "NCT05759208",
      "title": "The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "OK-101",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Okyo Pharma Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 240,
      "start_date": "2023-04-28",
      "completion_date": "2023-12-15",
      "has_results": false,
      "last_update_posted_date": "2024-02-09",
      "last_synced_at": "2026-10-23T05:22:27.032Z",
      "location_count": 6,
      "location_summary": "Newport Beach, California • Colorado Springs, Colorado • Louisville, Kentucky + 3 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Andover",
          "state": "Massachusetts"
        },
        {
          "city": "Shelby",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05759208"
    },
    {
      "nct_id": "NCT01675570",
      "title": "A Study of RX-10045 in the Treatment of Dry Eye Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye Syndrome"
      ],
      "interventions": [
        {
          "name": "RX-10045",
          "type": "DRUG"
        },
        {
          "name": "Vehicle for RX-10045",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "C.T. Development America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2012-08",
      "completion_date": "2012-11",
      "has_results": false,
      "last_update_posted_date": "2013-02-08",
      "last_synced_at": "2026-10-23T05:22:27.032Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01675570"
    },
    {
      "nct_id": "NCT01275105",
      "title": "A Single-Center, Randomized, Double-Masked, Placebo and Active Controlled, Dose-Ranging Evaluation of the Duration of Action of Brimonidine Tartrate Ophthalmic Solution in the Control of Ocular Redness Induced by Conjunctival Allergen Challenge (CAC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Allergic Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "Vehicle",
          "type": "DRUG"
        },
        {
          "name": "Brimonidine Tartrate 0.01%",
          "type": "DRUG"
        },
        {
          "name": "Brimonidine Tartrate 0.025%",
          "type": "DRUG"
        },
        {
          "name": "Oxymetazoline HCl 0.025%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eye Therapies, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 68,
      "start_date": "2011-01",
      "completion_date": "2011-03",
      "has_results": false,
      "last_update_posted_date": "2012-03-06",
      "last_synced_at": "2026-10-23T05:22:27.032Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01275105"
    },
    {
      "nct_id": "NCT06778434",
      "title": "The Effect of Topical Imipramine on Photodynamic Therapy-Mediated Immunosuppression on Forearms or Face on US Veterans",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Actinic Keratosis",
        "Imipramine",
        "Photodynamic Therapy"
      ],
      "interventions": [
        {
          "name": "Imipramine",
          "type": "DRUG"
        },
        {
          "name": "Control Vehicle",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2025-04-01",
      "completion_date": "2029-03-30",
      "has_results": false,
      "last_update_posted_date": "2025-12-22",
      "last_synced_at": "2026-10-23T05:22:27.032Z",
      "location_count": 1,
      "location_summary": "Dayton, Ohio",
      "locations": [
        {
          "city": "Dayton",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06778434"
    },
    {
      "nct_id": "NCT00984802",
      "title": "Safety and Efficacy of CMX-2043 in Subjects Undergoing Coronary Reperfusion Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stable Coronary Artery Disease",
        "Percutaneous Coronary Intervention"
      ],
      "interventions": [
        {
          "name": "CMX-2043",
          "type": "DRUG"
        },
        {
          "name": "Placebo control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ischemix, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 142,
      "start_date": "2010-02",
      "completion_date": "2011-04",
      "has_results": false,
      "last_update_posted_date": "2011-06-20",
      "last_synced_at": "2026-10-23T05:22:27.032Z",
      "location_count": 2,
      "location_summary": "Worcester, Massachusetts • Durham, North Carolina",
      "locations": [
        {
          "city": "Worcester",
          "state": "Massachusetts"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00984802"
    },
    {
      "nct_id": "NCT05409235",
      "title": "Nesvategrast (OTT166) in Diabetic Retinopathy (DR)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "OTT166",
          "type": "DRUG"
        },
        {
          "name": "Vehicle control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OcuTerra Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 225,
      "start_date": "2022-07-29",
      "completion_date": "2023-12-29",
      "has_results": true,
      "last_update_posted_date": "2024-08-09",
      "last_synced_at": "2026-10-23T05:22:27.032Z",
      "location_count": 67,
      "location_summary": "Peoria, Arizona • Phoenix, Arizona • Beverly Hills, California + 59 more",
      "locations": [
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05409235"
    },
    {
      "nct_id": "NCT03131154",
      "title": "SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-infectious Anterior Uveitis"
      ],
      "interventions": [
        {
          "name": "ADX-102 Ophthalmic Solution (0.5%)",
          "type": "DRUG"
        },
        {
          "name": "Vehicle of ADX-102 Ophthalmic Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aldeyra Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 123,
      "start_date": "2017-04-26",
      "completion_date": "2019-04-26",
      "has_results": true,
      "last_update_posted_date": "2025-02-10",
      "last_synced_at": "2026-10-23T05:22:27.032Z",
      "location_count": 27,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Prescott, Arizona + 24 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Prescott",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03131154"
    }
  ]
}